Search hospitals > Kansas > Manhattan
Cancer Center of Kansas-Manhattan
Claim this profileManhattan, Kansas 66502
Global Leader in Thyroid Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Relapse
108 reported clinical trials
2 medical researchers
Summary
Cancer Center of Kansas-Manhattan is a medical facility located in Manhattan, Kansas. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Breast cancer, Relapse and other specialties. Cancer Center of Kansas-Manhattan is involved with conducting 108 clinical trials across 287 conditions. There are 2 research doctors associated with this hospital, such as Shaker Dakhil, M.D. and Dennis F. Moore.Area of expertise
1Thyroid Cancer
Global LeaderStage IV
Stage II
Stage III
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Shaker Dakhil, M.D.Ascension Via Christi Hospitals Wichita6 years of reported clinical research
Expert in Thyroid Cancer
Expert in Lung Cancer
83 reported clinical trials
170 drugs studied
Dennis F. MooreAscension Via Christi Hospitals Wichita4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
30 reported clinical trials
80 drugs studied
Clinical Trials running at Cancer Center of Kansas-Manhattan
Breast Cancer
Lung Cancer
Bladder Carcinoma
Bladder Cancer
Breast cancer
Thyroid Cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Multiple Myeloma
Squamous Cell Carcinoma
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cancer Center of Kansas-Manhattan?
Cancer Center of Kansas-Manhattan is a medical facility located in Manhattan, Kansas. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Breast cancer, Relapse and other specialties. Cancer Center of Kansas-Manhattan is involved with conducting 108 clinical trials across 287 conditions. There are 2 research doctors associated with this hospital, such as Shaker Dakhil, M.D. and Dennis F. Moore.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.